Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

NCT02500576 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL: Aldesleukin
DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab
OTHER: Quality-of-Life Assessment
BIOLOGICAL: Therapeutic Tumor Infiltrating Lymphocytes

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]